287 related articles for article (PubMed ID: 34702252)
1. Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers.
Peng D; Wei C; Zhang X; Li S; Liang H; Zheng X; Jiang S; Han L
Cancer Cell Int; 2021 Oct; 21(1):566. PubMed ID: 34702252
[TBL] [Abstract][Full Text] [Related]
2. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
Front Immunol; 2022; 13():849592. PubMed ID: 35444654
[TBL] [Abstract][Full Text] [Related]
3. CTHRC1 is a Potential Prognostic Biomarker and Correlated with Macrophage Infiltration in Breast Cancer.
Wang Z; Zhang S; Zheng C; Xia K; Sun L; Tang X; Zhou F; Ouyang Y; Tang F
Int J Gen Med; 2022; 15():5701-5713. PubMed ID: 35755862
[TBL] [Abstract][Full Text] [Related]
4. CTHRC1 is a prognosis-related biomarker correlated with immune infiltrates in colon adenocarcinoma.
Meng C; Zhang Y; Jiang D; Wang J
World J Surg Oncol; 2022 Mar; 20(1):89. PubMed ID: 35307012
[TBL] [Abstract][Full Text] [Related]
5. Pan-cancer analysis reveals NAA50 as a cancer prognosis and immune infiltration-related biomarker.
Fang T; Wang D; Li R; Yu W; Tian H
Front Genet; 2022; 13():1035337. PubMed ID: 36568377
[No Abstract] [Full Text] [Related]
6. Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy.
Jia Y; Guo B; Zhang W; Wang F; Zhang Y; Zhang Q; Li E
Front Oncol; 2023; 13():1110207. PubMed ID: 37427102
[TBL] [Abstract][Full Text] [Related]
7. An Integrated Analysis Identified TAGLN2 As an Oncogene Indicator Related to Prognosis and Immunity in Pan-Cancer.
Pan T; Wang S; Wang Z
J Cancer; 2023; 14(10):1809-1836. PubMed ID: 37476180
[No Abstract] [Full Text] [Related]
8. CTHRC1 Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Kidney Renal Papillary Cell Carcinoma and Kidney Renal Clear Cell Carcinoma.
Zhou F; Shen D; Xiong Y; Cheng S; Xu H; Wang G; Qian K; Ju L; Zhang X
Front Oncol; 2020; 10():570819. PubMed ID: 33628726
[TBL] [Abstract][Full Text] [Related]
9. CTHRC1 expression is a novel shared diagnostic and prognostic biomarker of survival in six different human cancer subtypes.
Sial N; Ahmad M; Hussain MS; Iqbal MJ; Hameed Y; Khan M; Abbas M; Asif R; Rehman JU; Atif M; Khan MR; Hameed Z; Saeed H; Tanveer R; Saeed S; Sharif A; Asif HM
Sci Rep; 2021 Oct; 11(1):19873. PubMed ID: 34615943
[TBL] [Abstract][Full Text] [Related]
10. The molecular mechanisms of CTHRC1 in gastric cancer by integrating TCGA, GEO and GSA datasets.
Zhao L; Wang W; Niu P; Luan X; Zhao D; Chen Y
Front Genet; 2022; 13():900124. PubMed ID: 35928443
[TBL] [Abstract][Full Text] [Related]
11. High expression of Collagen Triple Helix Repeat Containing 1 (CTHRC1) facilitates progression of oesophageal squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation.
Wang C; Li Z; Shao F; Yang X; Feng X; Shi S; Gao Y; He J
J Exp Clin Cancer Res; 2017 Jun; 36(1):84. PubMed ID: 28645305
[TBL] [Abstract][Full Text] [Related]
12. Pancancer Analyses Reveal Genomics and Clinical Characteristics of the SETDB1 in Human Tumors.
Lin X; Xiao M; Chen Z; Ding C; Zhang T; Li Q
J Oncol; 2022; 2022():6115878. PubMed ID: 35656340
[TBL] [Abstract][Full Text] [Related]
13. Collagen triple helix repeat containing-1 negatively regulated by microRNA-30c promotes cell proliferation and metastasis and indicates poor prognosis in breast cancer.
Lai YH; Chen J; Wang XP; Wu YQ; Peng HT; Lin XH; Wang WJ
J Exp Clin Cancer Res; 2017 Jul; 36(1):92. PubMed ID: 28697793
[TBL] [Abstract][Full Text] [Related]
14. Pan-cancer analysis combined with experiments explores the oncogenic role of spindle apparatus coiled-coil protein 1 (SPDL1).
Song P; Wusiman D; Li F; Wu X; Guo L; Li W; Gao S; He J
Cancer Cell Int; 2022 Jan; 22(1):49. PubMed ID: 35093072
[TBL] [Abstract][Full Text] [Related]
15. CTHRC1 Is Associated With Immune Escape and Poor Prognosis in Gastric Cancer.
Hu Y; Huang L; Zhao K; Li Y; Givens NT; Heslin AJ; Deng Z; Cao L; Fang Y
Anticancer Res; 2023 Jan; 43(1):115-126. PubMed ID: 36585164
[TBL] [Abstract][Full Text] [Related]
16. Expression, Prognostic Value, and Biological Function of CTHRC1 in Different Types of Gliomas: A Bioinformatic Analysis and Experiment Validation.
Shi X; Zeng X; Jiao R; Yang Y; Du X; Qian J; Liu J; Chen G
Clin Med Insights Oncol; 2024; 18():11795549241260576. PubMed ID: 38894702
[TBL] [Abstract][Full Text] [Related]
17. CCNE1 is a predictive and immunotherapeutic indicator in various cancers including UCEC: a pan-cancer analysis.
Zheng X; Chen L; Liu W; Zhao S; Yan Y; Zhao J; Tian W; Wang Y
Hereditas; 2023 Mar; 160(1):13. PubMed ID: 36964635
[TBL] [Abstract][Full Text] [Related]
18. A Comprehensive Analysis of the Prognostic, Immunological and Diagnostic Role of CCNF in Pan-cancer.
Gao X; Bu H; Ge J; Gao X; Wang Y; Zhang Z; Wang L
J Cancer; 2023; 14(13):2431-2442. PubMed ID: 37670965
[No Abstract] [Full Text] [Related]
19. Overexpression of collagen triple helix repeat containing 1 (CTHRC1) is associated with tumour aggressiveness and poor prognosis in human non-small cell lung cancer.
Ke Z; He W; Lai Y; Guo X; Chen S; Li S; Wang Y; Wang L
Oncotarget; 2014 Oct; 5(19):9410-24. PubMed ID: 25238260
[TBL] [Abstract][Full Text] [Related]
20. A potential immunotherapeutic and prognostic biomarker for multiple tumors including glioma: SHOX2.
Wu X; Chen H; You C; Peng Z
Hereditas; 2023 May; 160(1):21. PubMed ID: 37170390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
